Quantum Biopharma Ltd. Files 6-K, Incorporates F-3 Registration
Ticker: QNTM · Form: 6-K · Filed: Aug 27, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $300,000, $1,300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, registration, compliance
TL;DR
Quantum Biopharma (fka FSD Pharma) filed a 6-K, referencing its F-3 registration. Standard compliance.
AI Summary
Quantum Biopharma Ltd., formerly FSD Pharma Inc., filed a Form 6-K on August 27, 2024, to incorporate by reference its registration statement on Form F-3 (SEC File No. 333-276264). The company is incorporated in A6 and its fiscal year ends on December 31. Its principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Why It Matters
This filing indicates that Quantum Biopharma Ltd. is updating or referencing its existing registration statement, which is a procedural step often related to future offerings or ongoing compliance.
Risk Assessment
Risk Level: low — This filing is primarily a procedural update and does not appear to contain new material financial or operational information that would significantly alter the company's risk profile.
Key Numbers
- 001-39152 — Commission File Number (Identifies the company's filing with the SEC)
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Registrant
- FSD Pharma Inc. (company) — Former name of registrant
- 333-276264 (other) — SEC File Number for Form F-3
- August 27, 2024 (date) — Filing date
FAQ
What is the purpose of incorporating the Form F-3 registration statement into this 6-K filing?
The filing states that the Form 6-K and its exhibits are incorporated by reference into the Registrant's Registration Statement on Form F-3 (SEC File No. 333-276264), indicating a procedural update or ongoing reference to its existing registration.
When was Quantum Biopharma Ltd. formerly known as FSD Pharma Inc.?
The filing mentions that Quantum Biopharma Ltd. was formerly known as FSD Pharma Inc. and notes a 'DATE OF NAME CHANGE: 20190327'.
What is the principal executive office address of Quantum Biopharma Ltd.?
The principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
What is the SIC code for Quantum Biopharma Ltd.?
The Standard Industrial Classification (SIC) code listed is 2834, which corresponds to Pharmaceutical Preparations.
Does Quantum Biopharma Ltd. file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F ☒'.
Filing Stats: 635 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-26 18:04:18
Key Financial Figures
- $300,000 — y's loan to Celly Nu was increased by CA$300,000 to CA$1,300,000 and (iv) made conformin
- $1,300,000 — lly Nu was increased by CA$300,000 to CA$1,300,000 and (iv) made conforming changes throug
Filing Documents
- fsd_6k.htm (6-K) — 17KB
- fsd_ex41.htm (EX-4.1) — 383KB
- fsd_ex42.htm (EX-4.2) — 21KB
- fsd_ex43.htm (EX-4.3) — 29KB
- fsd_ex44.htm (EX-4.4) — 159KB
- 0001654954-24-011100.txt ( ) — 610KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: August 26, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 3 EXHIBIT INDEX Exhibit Description Exhibit 4.1 Amended and Restated Exclusive Intellectual Property License Agreement dated August 14, 2024 by and between Quantum Biopharma Ltd., f/k/a FSD Pharma Inc., Celly Nutrition Corp., a British Colombia corporation, Celly Nutrition Corp., a Delaware Corporation and Lucid Psycheceuticals Inc., an Ontario corporation.* Exhibit 4.2 Intellectual Property Purchase Agreement dated October 2, 2023 by and between Quantum Biopharma Ltd., f/k/a FSD Pharma Inc. and Lucid Psycheceuticals Inc. * Exhibit 4.3 Amended and Restated General Loan Agreement dated as of April 3, 2024 made by and between Celly Nutrition Corp.,a British Colombia corporation in favor of Quantum Biopharma Ltd., f/k/a FSD Pharma Inc.* Exhibit 4.4 Amended and Restated General Security Agreement dated as of April 3, 2024 made by and between Celly Nutrition Corp., a British Colombia corporation in favor of Quantum Biopharma Ltd., f/k/a FSD Pharma Inc.* *Filed herewith 4